Answers are grounded in this paper and cite their sources.
Ozalin ® , a novel oral solution of 0.2% midazolam, is an effective option for moderate sedation prior to a therapeutic or diagnostic procedure, and as premedication before anaesthesia, in infants, children and adolescents. Orally administered midazolam has a rapid onset and short duration of action, with well-established favourable efficacy, tolerability, safety and acceptability profiles in these indications. To overcome the problems of bitter taste and inconsistent bioavailability associated with extemporaneous formulations of oral midazolam, Ozalin, a commercially prepared oral midazolam formulation, contains the inert excipient γ-cyclodextrin, which forms inclusion complexes with midazolam, thereby enhancing the solubility and stability of midazolam solutions, and masking its bitter taste. Ozalin is administered at the lowest dose of midazolam (i.e. 0.25 mg/kg) that has been shown to be effective, with this dose providing sedative effects consistent with the historical data for midazolam at doses that were the same or higher (i.e. 0.5–1.5 mg/kg).
No takes yet. Share an insight, caveat, or question.
Katherine A. Lyseng‐Williamson (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: